
Genenta Science (NASDAQ:GNTA) shares traded higher in Friday's premarket after the company unveiled an expanded collaboration with biotechnology firm ANEMOCYTE.
The partnership aims to advance the development of off-the-shelf lentiviral vector Plasmid DNA technology.